Biora licenses wound healing project to Molnlycke
This article was originally published in Clinica
Swedish company Biora has formed a licensing agreement with Molnlycke Health Care for a wound healing product, intended for use in the treatment of chronic skin ulcers. Molnlycke gets exclusive rights to develop and market the product worldwide, excluding Japan. Biora will get up to SKr45 million ($4.3 million), including SKr10 million upfront, from the arrangement.
You may also be interested in...
US FDA not planning an advisory committee for Pfizer/BioNTech’s request for authorization in 12-15-year olds at this time, but CDC’s ACIP is likely to weigh how to balance timing of COVID vaccination with administration of other immunizations generally recommended for adolescents.
HIV community is pushing back against the change, arguing that revenue lost from reduced reimbursement will cripple providers, which use the extra funds for wrap-around patient support and services.
Pfizer is looking to address breast cancer resistant to Ibrance and other CDK4/6 inhibitors, but sees potential paths to earlier lines of treatment and additional tumors.